Initiating Coverage on Cannabis Therapy Inc. (CTCO)

1 NBTEQUITIESRESEARCH 2014

NBT Equities Research LLC Cannabis Pharma

Tobin Smith, Chief Research Analyst September 18, 2014

Initiating Coverage on Cannabis Therapy Inc. (CTCO)

Ticker: CTCO: OTCQB Website: www.cannabistherapy.com Fully Diluted Shares Outstanding: 77.79 Million Float: 71.67 million Average Trading Volume: 21,000 Approximate Market Capitalization: $39 Million Current Share Price: .51 52-Week High/Low: $2.00/.44 12-18 Month Target: $1.50 based on 2016E revenues of 30 cents a share The Company: Cannabis Therapy Corporation CTC aims to become a leader in the research, development and commercialization of biopharmaceutical-grade, non-psychoactive cannabis based medicinal therapies and food supplements made from unregulated low-THC hemp cannabis in both humans and pet animals. Investment Thesis: Investors seeking exposure to the multibillion-dollar marijuana market are presented with a multitude of options, but many companies in the space remain a long way away from significant commercialization. Because of extensive existing academic research into biologic compounds found uniquely within cannabis sativa plants, there is an extensive business opportunity to apply world-class biotechnology and

bioscience compound development skill to unregulated low-THC hemp cannabis. The fastest go-to-market strategy is testing and creating patented medicinal compound extracts from non-regulated non-psychoactive compound CBD (Cannabidiol), the abundant and therapeutically active natural compound from the low-THC hemp cannabis plant. The experienced CTC biosciences team will specialize in biopharmaceutical-grade non-regulated OTC medicinal therapies and food supplements that will deliver multiple significant therapeutic applications for near-term commercial development. Specifically, CTC is developing proprietary CBD/Cannabidiol extraction methods and processes, offering highly refined, isolated cannabinoids as both extracts and products targeting the food science, therapeutic and medicinal food sectors. Business Model: The business plan is to apply CTCs world-class bioscience team to a vertically integrated grow/harvest/extract biologic system to: Develop, patent and manufacture biopharmaceutical-grade hemp-based extracts and sell them to branded OTC medicinal therapeutic companies and Acquire/license and manufacture hemp therapeutic products for direct marketing and wholesale distribution in both the human and pet alternative healthcare markets Recent Acquisition: CTC recently acquired the exclusive license to the fast growing line of hemp based dog/cat and horse therapeutics from Canna-Pet Inc. This acquisition should turn CTCO cash flow positive in 2015 and is emblematic of the commercialization opportunity in non-regulated hemp based bioactive




cannabinoid extract OTC medicinal products. If Marijuana were unknown, its discovery would no doubt be hailed as a medical breakthrough. Scientists would praise its potential for treating everything from pain to cancer and marvel at its rich pharmacopoeia The Economist Cannabis Medicinal Therapeutics Background: While the general approach to cannabis these days is commercializing its shall we say recreational properties, science is discovering cannabis to be a virtually unlimited source of wonder-drug like properties. Only in the last decade has progress in understanding the molecular mechanisms of natural medicinal aspects of cannabis. Key point: The Cannabis sativa plant produces over 483 chemical compounds, including 85 compounds known as phytocannabinoids that have not been detected in any other plant. Phytocannabinoids are the naturally occurring therapeutic components of cannabis plants (cannabis sativa) these are not synthetic products. Specifically, CBD (Cannabidiol) is the abundant and therapeutically active phytocannabinoid from the cannabis plant. CTC aims to harness the medicinal potential of the CBD phytocannabinoids and terpenes (essential oils) present within low-THC hemp plants in order to develop safe medicinally therapeutic products for treatment of inflammatory and auto-immune diseases. While most in the cannabis industry focus on the THC based therapeutic and recreational aspects of cannabis, the non-psychoactive phytocannabinoid therapeutic compounds derived from low-THC cannabis sativa hemp plants avoid critical regulatory issues still surrounding cannabis plants with the psychoactive THC compounds. Endocannabinoids, Phytocannabinoids, CBDs and the Human Health Few people are aware that the human endocannabinoid system is perhaps one of the most important physiological systems involved in establishing and maintaining human health. Undiscovered until 1988, an subject high restrictive regulations until 2004, researchers have now shown this group of agonists and their receptors are found throughout the human body and are instrumental in a variety of physiological processes including pain modulation, memory and appetite. Key point: Scientific study of the relationship between the human endocannabinoid system and the unique phytocannabinoids natural found in cannabis sativa was restricted until 2004. Understanding the science and relationship between the human endocannabinoid system and the therapeutic aspects of the phytocannabinoids unique to the cannabis sativa plant is in science terms a very young and under-researched field of opportunity.




Whats an Endocannabinoid? Endocannabinoids are a class of naturally occurring chemical compounds in humans that act on cannabinoid receptors to impact a multitude of normal physiological processes. Two types of cannabinoid receptors have been identified in humans, CB1 and CB2, which are distributed to different parts of the body. These receptors are specifically triggered by the bodys own endocannabinoids, as well as by phytocannabinoids of plant origin and synthetic cannabinoids.

The Science of Cannabinoid Receptors: Cannabinoid receptors are known as G protein-coupled receptors found in the plasma membrane of all human cells. One type of cannabinoid receptor, named CB1, has been identified as the most prevalent neurotransmitter system in the human brain, appearing also in the cerebellum and reproductive systems of both sexes. The second type of cannabinoid receptor, CB2, appears almost exclusively within the immune system and is identified as responsible for the anti-inflammatory effects of cannabis.

CBD (cannabidiol) is a metabolic sibling of THC, in that they are alike in many ways but are also different in important properties. CBD has no psychotropic effects and there are few CB2 receptors in the brain and peripheral nerves. The broader therapeutic profile associated with CBD includes:

Numerous disease states arise out of chronic inflammation; such as, depression, dementias including Alzheimer's, cancer, arthritis and other autoimmune disorders, viral infection, HIV, brain injury, etc.




The following is a list of the researched actions associated with some Cannabis sativa L. phytocannabinoids.




This image cannot currently be displayed.





How does CBD2 work in the body? Inflammatory cytokines can be activated by oxidative stress and disease states. Cannabinoids, being immunomodulators, work by interrupting the cytokine inflammatory cascade so that local inflammation does not result in tissue damage.

Key point: Phytocannabinoids stimulate human cannabinoid receptors, making them uniquely well suited to improve health and offer a wide range of therapeutic effects, including the potential to:

Reduce seizure frequency and improve epilepsy Provide anti-nausea and appetite improvement in debilitating diseases Improve insulin sensitivity Reduce anxiety and improve sleep Ease chronic pain- without making people feel high Reduce the severity of inflammatory and auto-immune diseases





Research is increasingly supporting the critical role of endocannabinoids in maintaining a healthy and balanced (i.e., homeostatic) human body. The CBD2 Commercialization Plan CBD (Cannabidiol) is the abundant and therapeutically active phytocannabinoid from the cannabis plantover 2000 cannabis strains with differing properties exist. CTC aims to deliver patented custom extract formulations for OTC consumer and animal therapies. These extract formulations harness the medicinal potential of the phytocannabinoids and terpenes (essential oils) made by low-THC hemp plants, to develop safe, medicinal products for treatment of inflammatory and auto-immune diseases in both humans and domesticated animals. Hemp Helps Bridge the Gap The U.S. government has taken few, if any, actions to try and regulate the hemp side of the industry since the early 2000s. Hemp foods have been fully legalized under federal law following a February 2004 court decision. In HIA v. DEA, the court ruled that the DEA could not regulate naturally occurring THC not contained within or derived from marijuana. The ruling means that non-psychoactive hemp is no longer included as a Schedule I Drug under the Controlled Substances Act governing marijuana in general. In February of this year, the U.S. governments bill contained a provision allowing universities and state agriculture departments to establish industrial hemp growing programs. These programs could pave the way towards commercial hemp farming becoming a reality in the U.S. Ten U.S. states have already passed laws enabling hemp cultivation, including Colorado, Washington, Montana, and Oregon. Significant Market Demand The potential for over-the-counter cannabinoid-based therapeutics is highlighted by the success of CBD-rich and THC-light strains like Charlottes Web. Developed by the Stanley brothers in 2011, the cannabis strain was created by crossbreeding a strain of marijuana with industrial hemp. The CBD-rich oil extracted from the strain, called Realm Oil or Alepsia is commonly used in cases of Dravet syndrome. Demand for Charlottes Web was so great that CBS Denver reported "there is now a growing community of 93 families with epileptic children using marijuana daily" adding that "hundreds are on a waiting list and thousands are calling." The potential for a hemp-only strain of cannabinoid-based oils, which could be legally sold throughout all 50 states, could prove highly successful over the long-term. Research Plan




The Companys strategic research plan is designed to establish a series of inflammation assays and models with the goal of developing a hemp-extract profiling platform. This platform will enable identification and characterization of those hemp strains that are ideal for development of specific anti-inflammatory products. The extract profiling platform will play a key role in advancing new hemp-based products and in turning the companys current hemp

crop into product prototypes for testing and manufacture. Cannabis Therapys researchers are focused on potential applications specific to inflammatory and autoimmune diseases, such as inflammatory bowel disease, arthritis, and psoriasis. "Inflammation plays a significant role in a multitude of diseases and hemp based, anti-inflammatory products could potentially have widespread applications," said Cannabis Therapy President & CEO Dr. Soren Mogelsvang. "We have long held the belief that cannabinoids have enormous medicinal potential and are eager to apply our extensive R&D backgrounds in this critical phase of product development." By holding their laboratory research to the gold standards of current pharmaceutical practices, Cannabis Therapy Corp is aligning itself to be at the forefront of change leadership when the federal government updates their regulations. World Class Research & Development Team Leading the research behind the company is a trio of world-class scientists. President & CEO of the company is Dr. Soren Mogelsvang, who has a PhD in Biochemistry from Cambridge University, an MSc in Plant Molecular Biology from the University of Copenhagen, as well as having authored several patent applications, grants and publications. Dr. Cohava Gelber has over 25 years of experience in the discovery and development of immune therapeutics and diagnostics for cancers, allergies, autoimmune and infectious diseases. Dr. Gelber has the honor of holding both a PhD and a MBA; this has led to a distinguished career with positions at Duke University, ImmuLogic Pharmaceutical Corp, and Molecular Discoveries amongst others. Ms. Vered Caplan, who holds a variety of degrees ranging from a M.Sc. in bio-medical engineering (Tel-Aviv University) to a B.Sc. in mechanical engineering (Technion Institute) is currently the CEO of Orgenesis, Inc., a development stage company offering therapeutic technology as a treatment for diabetes. The research team is fully qualified to determine the optimal yield, quality, and potency of




different cannabinoid extracts, while simultaneously focusing on expanding the companys intellectual property. This expansion of intellectual property as a commercially viable product mix is a key aspect of the companys plan for a short-term path to monetization. Cannabis Therapy Corp has identified several hemp strains that are rich in CBD (one of the pharmaceutically active components of the cannabis plant) and extremely low in THC (the psychoactive component). Collaborative efforts with academic researchers and growers are being pursued to identify and further develop strains with maximum medicinal potential, and to strengthen CTCs proprietary position. Relying on proprietary extraction and purification methods, combined with potency testing in bioassays, the Companys team of highly experienced biomedical researchers will utilize these unique hemp strains to produce high-quality, non-psychoactive (no-high) and safe products for treatment of different diseases and ailments. Go-to-Market Strategy As mentioned, CTC research is aimed at supporting the development of pharmaceutical-grade, cannabis-derived products for the OTC medicinal therapeutics sector. Nutritional or functional foods contain natural unregulated compounds demonstrated to have a physiological benefit or provide relief from chronic diseases and ailments. Functional foods range from isolated nutrients, dietary supplements, and herbal products to specific diets and processed foods and beverages. Once the company is able to establish scientifically validated assays, they plan on immediately establishing a twofold strategy including potentially partnering with existing product manufacturers. This strategy will allow Cannabis Therapy Corp to start driving revenues on a shortened timeline. The added benefit of launching the product line as over-the-counter nutritional supplements or functional foods allows for distribution in all 50 states. Again this is possible because the product is derived from the Hemp plant, which contains very little THC and is now able to be grown legally across the US with the passage of the 2014 Farm bill. Hemp Cultivation Cannabis Therapy is supporting their research and development activities with its own partnered hemp production. On June 25, 2014, the company announced that their initial crop of hemp cultivars are exhibiting normal growth characteristics and looking very healthy. These crops are being grown and managed by their experienced partners at Rocky Mountain Hemp Inc., and will be harvested in approximately 60-75 days. "Working with a fourth generation Colorado farmer has provided us with a real advantage towards reestablishing the domestic hemp industry over many other growers Given the pace of growth and potential yield of our crop, we currently believe this initial acreage will adequately deliver a regional source of natural, low-THC cannabinoids," added Dr. Mogelsvang in a




separate press release. Near-term Catalysts The commencement of laboratory research represents one of the most important steps in bringing this type of product mix to market over the near-term, and sets the company apart from competitors in the industry like Cannabis Sciences Inc. (CBIS) or Hemp Inc. (HEMP). The Canna-Pet, LLC Acquisition Under the terms of the agreement, Cannabis Therapy Corp., in exchange for sales royalties, now has an exclusive worldwide license and rights to the technology and products currently developed by Canna-Pet, LLC and the possibility for co-development of future animal health products. The agreement covers production and sale of animal health and pet products made from hemp, a low-THC cannabis plant and results in the transfer of future revenues, brand identity, management expertise, goodwill, sales materials and customer base from Canna-Pet, LLC to Cannabis Therapy Corp. The animal health sector encompasses livestock and working animals as well as pets. Whether an animal has high intrinsic value or is a valued family member, quality assured, pharmaceutical grade products are in great demand and significantly aid in the creation of trusted, high value brands. According to a State of the American Pet Survey, one of the greatest challenges of pet ownership is maintaining pets' health. 41% of pet owners have considered or tried various alternative therapies, including nutritional supplements (29%), herbal remedies (7%) and homeopathy (4%). Canna-Pet products were developed in collaboration between Doctors of Veterinary Medicine in six states and an MIT entrepreneur. The company is the culmination of twenty years of research and development in cannabinoid therapies for animals. Canna-Pet, LLC currently leads the industry with veterinarian recommended, legal, over the counter Cannabidiol (CBD) products for pets made in the USA from industrial hemp. www.canna-pet.com. Says Dan Goldfarb, President of Canna-Pet, LLC. "The recession-resistant animal health products industry is projected to reach $12 billion in the USA alone by 2016 and to-date we have made great progress in pioneering an industry segment that we believe is poised to explode globally. Twenty years of animal research mirrors many current human studies indicating that CBD therapies can assist with inflammation, anxiety, compromised immune systems, digestive issues, nausea, chronic pain and seizures. Our relationship with Cannabis Therapy Corp. complements their ongoing human health science R&D efforts while rapidly elevating our core science competency, operational and financial planning well beyond what we have developed to-date." Cannabis Therapy Corp. President and CEO Dr. Soren Mogelsvang states Providing hemp-based, veterinary-grade extracts to the rapidly growing but undervalued over the counter animal




health market is simply the first of several revenue streams currently available to us in the medicinal cannabis marketplace. About Canna-Pet Products for Pet Health Developed in collaboration between Doctors of Veterinary Medicine in six states and an MIT entrepreneur, Canna-Pet products are the culmination of twenty years of research and development in cannabinoid therapies for animals. Canna-Pet, LLC currently produces the only veterinarian recommended, legal, over the counter CBD products for animals, made from industrial hemp and manufactured in the USA. Canna-Pet products are offered as capsules in four dosages, and as Canna-Biscuits treats. All products contain not only CBD, but other cannabinoids and terpenes (essential oils) that make Canna-Pet products uniquely effective. Canna-Pet, LLC products are available worldwide. For more information visit: www.canna-pet.com. Why you should choose Canna-Pet All Natural Cannabis has been safely and effectively used as a naturopathic medicine for thousands of years. Phytocannabinoids, terpenoids, and flavonoids are compounds in cannabis that naturally interact with the nervous and immune systems of animals. 100% Safe Industrial Hemp is naturally rich in these therapeutic compounds - especially cannabidiol (CBD). There are ZERO negative side effects and NO medical conflicts. There is almost zero THC and your pet will not get "high" or in trouble with the law. Veterinarian Recommended Developed in collaboration between Doctors of Veterinary Medicine and an entrepreneur from the Massachusetts Institute of Technology. Now available over-the-counter. The only legal pet products with CBD. Cruelty-Free No animal has EVER been harmed by taking Canna-Pet, and no animals have ever been harmed in any of our testing or product development. Canna-Pet is 100% cruelty-free, organic, non-GMO, and vegan. Made in the USA.




Completely Legal Hemp is legal to buy or sell everywhere in the USA, Canada, UK, France, Japan, Spain, Ireland, Germany, Poland, Hungary, Egypt, Netherlands, Israel, Sweden, Denmark, Portugal, Russia, Switzerland, Belgium, India, Austria, Chile, Peru, Estonia, Romania, Finland, Australia, Italy, and Ukraine. Evolving Canna-Pet uses proprietary production methods and our unique golden ratio of cannabinoids. Not just more CBD, more of everything - in the right ratios. With over 10,000,000 capsules produced for pets in 25 countries, Canna-Pet is the global innovator in cannabinoid therapy.

The National Cancer Institute Animal studies find cannabinoids have antitumor effects, anti-inflammatory effects, stimulate and regulate appetite, and modulate pain, without psychoactive effect. DVMs Observe Improved vitality and overall health. Reduction in aggression, anxiety and behavior problems. Reduction of arthritic pain and digestive issues (IBD, diarrhea and constipation), reduction in nausea and improved appetite, improved quality of life, outstanding for palliative care. Behavior Issues?




Helps with aggression disorders, noise phobias, anxiety, self-trauma, cognitive disorders and dementia (canine), marking and spraying (feline), sleep disorders, OCD, excessive vocalization and inappropriate urination. Great for easing travel, rehoming, or grooming, reducing stress during thunderstorms and fireworks, and separation anxiety. Health Canada Therapeutic indications such as psychosis, epilepsy, anxiety, sleep disturbances, neurodegeneration, cerebral and myocardial ischemia, inflammation, pain and immune responses, emesis, food intake, type-1 diabetes, liver disease, osteogenesis, and cancer. Supplemental Therapy When used in conjunction with traditional therapies cannabinoids often allow for much lower dosing of drugs that have potential negative side effects. Canna-Pet augments other medications and allows for a more balanced, multimodal approach to caring for your pet. We Recommend Canna-Pet as a daily food additive for all pets, but especially for those with arthritis, allergies, anxiety or behavior issues, compromised immune systems, diabetes, digestive issues, nausea, chronic pain, cancer and seizures. Common questions about Canna-Pet What's the cost? $1 per dose. $1.50 for Giant size. Cats use one dose per day (QD), while dogs require two doses per day (BID). Results are obvious within days. Does this help with...? Try it! We find medical benefits, behavioral benefits, prolonged life, reduced stress, and improved quality of life with our pets. Is this legal? YES, we produce the ONLY legal cannabidiol products for pets - because we use industrial hemp, imported from Europe & Canada. Will this get my pet "high"?




NO, our products have near zero THC, they are made with industrial hemp. This ensures they are safe and legal. How many mg of...? Click HERE for our technical white paper. Now using our golden ratio for maximum therapeutic effect. How do I administer it? Put capsule in a treat, or sprinkle powder into food, or mix with liquid. Pets rarely mind the taste. Detailed Instructions Vet Recommended? YES, over 200 DVMs in the USA and Canada refer clients to Canna-Pet. How many Canna-Pets? Currently helping over 1,000,000 pets, in all 50 states, Canada & Europe. Does this conflict with...? NO, there are no medical conditions and ZERO medications that conflict. You can start or stop at any time. Safe & Effective? YES. Specialized facilities, proprietary production methods, and our golden ratio provide consistent results. Customized? YES, we select from four different dosages based on the size, age and medical conditions of your pet. How long for results? We expect you to notice results within days, and guide your administration. Maximum CBD capsules? Yes, we have new Maximum CBD capsules that contain up to 12X as much cannabidiol.




Which capsule to buy? If you are new to Canna-Pet, start with our standard capsules. Max CBD is for special applications. More info. Canna-Biscuits? That's right! Canna-Biscuits are available in several flavors, using our Maximum CBD formula. Even More Information General Questions Technical Information Covered by Trupanion Pet Insurance as Herbal Therapy

Canna-Pet Business Sales of Canna-Pet products to date have reported reached >$70,000 monthly and are 100% e-commerce based. Gross margins exceed 75% and customer re-order rates after initial orders reportedly exceed 60%--a very high re-order rate The short-term plan is to expand the direct marketing team and include physical pet store distribution and marketing. Until forbid automated re-ordering systems will improve customer retention and should increase average sale per order. Risk Factors CTCO is a development stage company with limited monthly revenues from its Aug 2014 acquisition of Canna-Pet LLC. CTCO is engaged in the research and development of CBD based compounds from hemp cannabis plants. No guarantee of the discovery or commercialization of any new compound(s) or applications is made or inferred.




CTCO is listed on the OTCQB exchange with low trading volume (under 20,000 shares a day on average). Your ability to acquire and/or sell significant quantities on CTCO shares on any single trading day will be limited. CTCO will be raising capital to fund operation costs and such funding will dilute present shareholder equity percentages to the degree current investors do not participate in such offerings. Research Studies Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects National Cancer Institute - 37 Animal Studies on Cannabinoids National Cancer Institute - 46 Human Studies on Cannabinoids British Journal of Pharmacology, Volume 163, Issue 7 - 19 Articles on Cannabinoids Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity Health Canada Cannabis Information CB: therapeutic target-in-waiting. Phytocannabinoids and endocannabinoids. Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents Delayed disease progression in ALS mice by treatment with a cannabinoid Marijuana in the management of amyotrophic lateral sclerosis Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials Cannabis Relieves Lou Gehrigs Symptoms Prevention of Alzheimer's Disease Pathology by Cannabinoids Marijuana Slows Alzheimer's Decline Cannabinoids reduce the progression of Alzheimer's disease in animals Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Cannabinoids and bone: friend or foe? Role of cannabinoids in the regulation of bone remodeling. Role of cannabinoid 2 receptor in the development of bone cancer pain. [Chinese] A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Reduction of Bone Cancer Pain by Activation of Spinal Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the Spinal Cord in a Murine Model of Bone Cancer Pain Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. The emerging role of the endocannabinoid system in cardiovascular disease. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Marijuana Extract Helps Arthritis Pain Rheumatoid arthritis, Cannabis based medicine eases pain and suppresses disease Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. The endocannabinoid system and energy metabolism. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs. The cannabinoid 9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity. Cannabinoids in eating disorders and obesity.




[Cannabinoid system and feeding regulation]. [Spanish] Endogenous cannabinoid system as a modulator of food intake. The endocannabinoid system and the treatment of obesity. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. [Endocannabinoid system and energy metabolism: physiology and pathophysiology]. [Italian] Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. A Comparison of the Ocular and Central Effects of 9-Tetrahydrocannabinol and Cannabigerol. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. The endocannabinoid system as a target for the treatment of motor dysfunction. The endocannabinoid system in Huntington's disease. Prospects for cannabinoid therapies in basal ganglia disorders. Cannabinoids and Parkinson's disease. Cannabinoids and neuroprotection in motor-related disorders. Stimulation of CB1 Cannabinoid and NMDA Receptors Increases Neuroprotective Effect against Diazinon-Induced Neurotoxicity Role of CB2 receptors in neuroprotective effects of cannabinoids. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Subcellular localization of NAPE-PLD and DAGL- in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. 9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer through Cdc2 Regulation Cannabidiol inhibits tumour growth in leukaemia and breast cancer in animal studies Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Antibacterial Cannabinoids from Cannabis sativa: A StructureActivity Study [Cannabis and cannabinoids as drugs] Article in Norwegian. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Pharmacological actions of cannabinoids. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Comparative metabolism of cannabidiol in dog, rat and man. Cannabidiol-caused depression of spinal motoneuron responses in cats. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Evidence for novel cannabinoid receptors. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Therapeutic potential of cannabinoids in CNS disease. The neurobiology and evolution of cannabinoid signalling. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Regulation of nausea and vomiting by cannabinoids. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. The cannabinoid system and pain: towards new drugs?]. [French] Vascular targets for cannabinoids: animal and human studies Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. [The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?]. [French]




Cardiovascular Pharmacology Time-dependent vascular actions of cannabidiol in the rat aorta Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1 Possible endocannabinoid control of colorectal cancer growth The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3KAKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells The cannabinoids as potential antiepileptics. Cannabinoids: Defending the Epileptic Brain Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions? Marijuana treatments for autoimmune disorders Cannabidivarin is anticonvulsant in mouse and rat. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor1 Cannabinoids, endocannabinoids, and cancer. Critical appraisal of the potential use of cannabinoids in cancer management Cannabinoids as potential new therapy for the treatment of gliomas A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells Cannabidiol Enhances the Effects of 9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival Cannabis: discrimination of "internal bliss"? Cannabis: pharmacology and toxicology in animals and humans. The Endocannabinoid System as an Emerging Target of Pharmacotherapy The pharmacology of cannabinoid receptors and their ligands: an overview. Cannabinoids, immune system and cytokine network. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Antineoplastic activity of cannabinoids. Cannabinoids induce incomplete maturation of cultured human leukemia cells Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway Cannabidiol-Induced Apoptosis in Human Leukemia Cells : A Novel Role of Cannabidiol in the Regulation of p22phox and Nox4 Expression Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas Delta-9Tetrahydrocannabinol inhibits growth and metastasis of lung cancer Marijuana Cuts Lung Cancer Tumor Growth In Half, Study Shows Cannabinoid receptors as novel targets for the treatment of melanoma Cannabinoid receptor-1 modulation induces apoptosis of human melanoma cells Cannabinoids Ameliorate Pain and Reduce Disease Pathology in Cerulein-Induced Acute Pancreatitis Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum StressRelated Genes The endocannabinoid signaling system in cancer Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Introduction to secondary metabolism in cannabis Celery, artichokes contain flavonoids that kill human pancreatic cancer cells Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro Antimicrobial activity of flavonoids The effects of dietary flavonoids on the regulation of redox inflammatory networks




Advantages of polypharmaceutical herbal Cannabis compared to single-ingredient, synthetic tetrahydrocannabinol Predator threat stress promotes long lasting anxiety-like behaviors and modulates synaptophysin and CB1 receptors expression in brain areas associated with PTSD symptoms. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Cannabis Finds Its Way into Treatment of Crohn's Disease. Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Cloning and pharmacological characterization of the dog cannabinoid CB receptor. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme Anti-inflammatory effects of Cannabinoid 2 Receptor activation in endotoxin-induced uveitis Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice. The genetic ablation or pharmacological inhibition of TRPV1 signaling is beneficial in the restoration of quiescent osteoclast activity in ovariectomized mice Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brain Cannabidiol: An Overview of Some Pharmacological Aspects Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Behavioral effects of cannabinoid agents in animals. Endocannabinoids in liver disease. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model. Endocannabinoid chemical biology: a tool for the development of novel therapies. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. In vitro metabolism of cannabichromene in seven common laboratory animals. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by (9)-tetrahydrocannabinol. In vitro metabolism of cannabinol in rat, mouse, rabbit, guinea pig, hamster, gerbil and cat. In vitro metabolism of cannabigerol in several mammalian species. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease A Comparison of the Ocular and Central Effects of 9-Tetrahydrocannabinol and Cannabigerol Comparative in vitro metabolism of the cannabinoids. How CBD May Cause Cancer Cells to Die in Brain Tumors Role of 5-HT1 receptors of accumbens shell arenaupon ACPA-induced anxiolytic-like behaviors in rat Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Endocannabinoids and the haematological system Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Cannabinoids in pancreatic cancer: Correlation with survival and pain Toward drugs derived from cannabis. Cannabinoids: Potential Anticancer Agents Cannabidiol as potential anticancer drug. Inhibition of tumor angiogenesis by cannabinoids Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1 Anticonvulsant properties of linalool Limonene & How to Manage Symptoms of Gastroesophageal Reflux Disease D-Limonene: safety and clinical applications. Chemoprevention and therapy of cancer by d-limonene. Cannabinoids for Cancer Treatment: Progress and Promise Anticonvulsant properties of linalool in glutamate-related seizure models. Gastroprotective mechanisms of Citrus lemon (Rutaceae) essential oil and its majority compounds limonene and -pinene Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents Antitumorigenic Effects of Cannabinoids beyond Apoptosis




Cannabidiol arrests onset of autoimmune diabetes in NOD mice Cannabidiol lowers incidence of diabetes in non-obese diabetic mice Natural Products Evaluated in Neuropathic Pain Models A Systematic Review Beta-caryophyllene is a dietary cannabinoid The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain -Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Effects of cannabidiol in animal models predictive of antipsychotic activity. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Cannabinoid modulation of prefrontallimbic activation during fear extinction learning and recall in humans Beneficial effects of a Cannabis sativa extract on diabetes induced neuropathy and oxidative stress Marijuana: The Next Diabetes Drug? Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile Industrial hemp decreases intestinal motility stronger than indian hemp in mice. The cellular processing of the endocannabinoid anandamide and its pharmacological manipulation Flavonoids A Study of Infraspecific Flavonoid Variation of Cannabis Sativa L. Phytocannabinoids beyond the Cannabis plant do they exist? Cannabis as a medicament Cannabinoid and Terprnoid Reference Guide Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? The draft genome and transcriptome of Cannabis sativa A Chemotaxonomic Analysis of Cannabinoid Variation in Cannabis (Cannabaceae) Influence of Agroclimatic Conditions on Content of Main Cannabinoids in Industrial Hemp (Cannabis sativa L.) Feasibility of Industrial Hemp Production in the United States Pacific Northwest Industrial Hemp: Global Markets and Prices Hemp as an Agricultural Commodity Collection of Hemp Research DISCLOSURE & DISCLAIMER

This report has been prepared and distributed by Velocity Studio, LLC dba NBT Equities Research. This report is based on sources that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. All information contained herein is subject to change without notice. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Statements included in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues. Our professionals may provide oral or written market commentary that reflects opinions that are contrary to the opinions expressed in this report. The price and value of the investment referred to in this report may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. Electronic report is simultaneously available to all recipients in any form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof.

DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised Velocity Studio LLC dba NBT Equities Research (NBT) has been compensated $50,000 in 144 restricted stock for sponsored research and investor awareness services on behalf of Cannabis Therapy Corp (CTCO). NBT reserves to right to buy, hold or sell any shares it holds in CTCO at any time including sales during the time period of this or any investor awareness campaign and it should be assumed shares will be sold during the distribution of this or any advertisement on behalf of CTCO.




NBT has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) The party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.

Initiating Coverage on Cannabis Therapy Inc. (CTCO)

Documents

Transcript of Initiating Coverage on Cannabis Therapy Inc. (CTCO)